-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $48

Benzinga·11/10/2026 11:18:57
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $47 to $48.